Literature DB >> 30566761

More evidence on the limited impact of state oral oncology parity laws.

Aaron N Winn1,2,3, Stacie B Dusetzina4,5.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30566761      PMCID： PMC6361375          DOI： 10.1002/cncr.31904

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  5 in total

1.  The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer.

Authors:  Alexander L Chin; Jason P Bentley; Erqi L Pollom
Journal:  Cancer       Date:  2018-12-19       Impact factor: 6.860

2.  The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.

Authors:  Joan M Neuner; Sailaja Kamaraju; John A Charlson; Erica M Wozniak; Elizabeth C Smith; Alana Biggers; Alicia J Smallwood; Purushottam W Laud; Liliana E Pezzin
Journal:  J Natl Cancer Inst       Date:  2015-05-12       Impact factor: 13.506

3.  The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.

Authors:  Dawn L Hershman; Jennifer Tsui; Jay Meyer; Sherry Glied; Grace Clarke Hillyer; Jason D Wright; Alfred I Neugut
Journal:  J Natl Cancer Inst       Date:  2014-10-27       Impact factor: 13.506

4.  Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.

Authors:  Stacie B Dusetzina; Haiden A Huskamp; Aaron N Winn; Ethan Basch; Nancy L Keating
Journal:  JAMA Oncol       Date:  2018-06-14       Impact factor: 31.777

5.  Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations.

Authors:  Ann Butler Nattinger; Liliana E Pezzin; Emily L McGinley; John A Charlson; Tina W F Yen; Joan M Neuner
Journal:  Springerplus       Date:  2015-02-03
  5 in total
  2 in total

1.  Medical Financial Hardship Intensity and Financial Sacrifice Associated with Cancer in the United States.

Authors:  Xuesong Han; Jingxuan Zhao; Zhiyuan Zheng; Janet S de Moor; Katherine S Virgo; K Robin Yabroff
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-01-15       Impact factor: 4.254

2.  Socioeconomic Factors and Survival of Multiple Myeloma Patients.

Authors:  Kamal Chamoun; Amin Firoozmand; Paolo Caimi; Pingfu Fu; Shufen Cao; Folashade Otegbeye; Leland Metheny; Seema Patel; Stanton L Gerson; Kirsten Boughan; Marcos De Lima; Ehsan Malek
Journal:  Cancers (Basel)       Date:  2021-02-03       Impact factor: 6.575
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.